Impact of Postoperative Oral Administration of UFT for Completely Resected pT2N0 Non-Small Cell Lung Cancer.
- Author:
Jin Gu LEE
1
;
Kyung Young CHUNG
;
Inkyu PARK
;
Dae Joon KIM
;
Kil Dong KIM
;
Sang Ho CHO
Author Information
1. Department of Thoracic and Cardiovascular Surgery, Yonsei University College of Medicine, Korea. kychu@yumc.yonsei.ac.kr
- Publication Type:Original Article ; Randomized Controlled Trial
- Keywords:
Adjuvant therapy;
Lung neoplasm
- MeSH:
Adenocarcinoma;
Administration, Oral*;
Carcinoma, Non-Small-Cell Lung*;
Chemotherapy, Adjuvant;
Compliance;
Disease-Free Survival;
Follow-Up Studies;
Humans;
Lung;
Lung Neoplasms;
Recurrence;
Survival Rate
- From:The Korean Journal of Thoracic and Cardiovascular Surgery
2007;40(6):428-434
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Recent studies have suggested that UFT may be an effective adjuvant therapy for completely resected IB (pT2N0) non-small cell lung cancer (NSCLC). We designed this study to clarify the feasibility of performing adjuvant chemotherapy with UFT for completely resected IB non-small cell lung cancer. MATERIAL AND METHOD: We randomly assigned patients suffering with completely resected IB non-small cell lung cancer to receive either UFT 3g for 2 year or they received no treatment. All patients had to be followed until death or the cut-off date (December 31 2006). RESULT: From June 2002 through December 2004, 64 patients were enrolled. Thirty five patients were assigned to receive UFT(the UFT group) and 29 patients were assigned to observation (the control group). A follow-up survey on the 3 year survival rate was successfully completed for all the patients. The median follow-up time for all the patients was 32.8 months. In the UFT group, the median time of administration was 98 weeks (range: 2~129 weeks). The rate of compliance was 88.2% at 6 months, 87.5% at 12 months, 80.6% at 18 month and 66.7% at 24 months. Seven recurrences (24.1%) occurred in the control group and six (17.1%) occurred in the UFT group (p=0.489). The three-year disease free survival rate was 71.3% for the control group and 82.0% for the UFT group (p=0.331). On the subgroup analysis, the three-year disease free survival rate for the patients with adenocacinoma was 45.0% for the control group and 75.2% for the UFT group (p=0.121). The three-year disease free survival rate for the patients with non-adenocarcinoma was 88.1% for the control group and 88.9% for the UFT group (p=0.964). CONCLUSION: Postoperative oral administration of UFT was well-tolerated. Adjuvant chemotherapy with UFT for completely resected pT2N0 adenocarcinoma of the lung could be expected to improve the disease free survival, but this failed to achieve statistical significance. A prospective randomized study for a large number of patients will be necessary.
